Andreas Grauer

Romosozumab and Teriparatide Effects on Vertebral Cortical Mass, Thickness, and Density in Postmenopausal Women With Low Bone Mineral Density (BMD).

Andrew H. Gee, Graham M. Treece, Tristan Whitmarsh, 2014 .

Romosozumab in postmenopausal women with low bone mineral density

Cesar Libanati, Steven Boonen, Michael R McClung, 2014, The New England journal of medicine.

Effects of Romosozumab Compared With Teriparatide on Bone Density and Mass at the Spine and Hip in Postmenopausal Women With Low Bone Mass

Klaus Engelke, Thomas Fuerst, Cesar Libanati, 2017, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data.

P. Kostenuik, A. Grauer, D. Dempster, 2012, Clinical therapeutics.

Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis.

Richard Eastell, Christian Roux, R. Eastell, 2007, The Journal of clinical endocrinology and metabolism.